Immunotherapy has been a game-changer for treating solid tumors. By harnessing and strengthening the body’s immune defenses, these treatments allow our immune cells to better recognize and target tumor cells for elimination. Some immunotherapy strategies take advantage of neoantigens to develop vaccines or T cell therapies.
Julie Rumble, Ph.D.,
You may immediately recognize the prefix “neo” derived from Greek neos meaning “new” or “novel.” Tumor neoantigens are just that, new antigens.
How do they come to exist? One major mechanism for their formation is the genomic instability typical of cancer cells. Increased mutational burden means that cancer cells may express proteins, not typically present in normal tissues or just simply having the wrong sequence. Within tumors, new protein sequences not expressed anywhere else in the body are great candidates for immunotherapy.
Marvin Gee, Ph.D.,
T cell responses are at the center of neoantigen-based immunotherapies.
Neoantigens must be presented by MHC molecules to induce an immune response. MHC presentation means that neoantigens are accessible for T cell recognition (CD8+ and CD4+ T cells) and have the potential to trigger activation and T cell expansion.
Michael Zhou, Ph.D.,
Neoantigens are considered as non-self, thus more immunogenic.
Neoantigens are highly individual/cancer-specific and unlikely to escape from central tolerance.
TCRs might recognize certain neoantigens to accelerate adoptive T cell therapies.
Julie Rumble, Ph.D.,
Your workflow starts at the tumor site for identifying neoantigens.
Once you have isolated tumor cells and processed them for purification of MHC-bound peptides, mass analysis (i.e., LC-MS/MS) combined with the use of databases will allow you to identify a number of tumor antigen peptides.
Whether these tumor-derived proteins are in fact neoantigens and immunogenic enough can only be demonstrated by in vitro testing.
To validate neoantigens, you may rely on different in vitro methods. For example, proteins with sequences of interest may be overexpressed for validation of MHC I peptides.
Alternatively, you may choose to incubate cells with synthetic soluble peptides allowing direct MHC I presentation.
For MHC II peptides the in vitro approach is different, as you will want to ensure protein uptake by phagocytosis for endolysosomal processing.
High-throughput Identification of Intracellular Targets for Solid Tumors
Target identification in solid tumors can help enable therapeutic development against indications of high unmet need and across a wide patient population.
Neoantigen immunopeptidome profiling and production for personalized immuno-oncology therapeutic discovery
Neoantigen based immuno-oncology therapies are proving promising, but neoantigen identification and production are bottlenecks to boosting efficacy.
TIDES TV Interview: Neoantigen Peptides in Personalized Cancer Immunotherapy
Neoantigen based personalized immuno-oncology drugs are a relatively new therapeutic avenue that have shown strong anti-tumor efficacy in the clinic.
Are you ready to take advantage of our full spectrum of high-quality peptide services? Explore Peptide Services Now!